ZA200203171B - Positive modulators of nicotinic receptor agonists. - Google Patents

Positive modulators of nicotinic receptor agonists.

Info

Publication number
ZA200203171B
ZA200203171B ZA200203171A ZA200203171A ZA200203171B ZA 200203171 B ZA200203171 B ZA 200203171B ZA 200203171 A ZA200203171 A ZA 200203171A ZA 200203171 A ZA200203171 A ZA 200203171A ZA 200203171 B ZA200203171 B ZA 200203171B
Authority
ZA
South Africa
Prior art keywords
receptor agonists
nicotinic receptor
positive modulators
modulators
positive
Prior art date
Application number
ZA200203171A
Other languages
English (en)
Inventor
David Gurley
Thomas Lanthorn
John Macor
James Rosamond
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200203171B publication Critical patent/ZA200203171B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA200203171A 1999-11-03 2002-04-22 Positive modulators of nicotinic receptor agonists. ZA200203171B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903997A SE9903997D0 (sv) 1999-11-03 1999-11-03 New compounds

Publications (1)

Publication Number Publication Date
ZA200203171B true ZA200203171B (en) 2003-09-23

Family

ID=20417607

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203171A ZA200203171B (en) 1999-11-03 2002-04-22 Positive modulators of nicotinic receptor agonists.

Country Status (16)

Country Link
US (1) US6750242B1 (enExample)
EP (1) EP1230216A1 (enExample)
JP (1) JP2003513071A (enExample)
KR (1) KR20020063176A (enExample)
CN (1) CN1239482C (enExample)
AU (1) AU783507B2 (enExample)
BR (1) BR0015195A (enExample)
CA (1) CA2387745A1 (enExample)
CO (1) CO5251458A1 (enExample)
IL (1) IL149098A0 (enExample)
MX (1) MXPA02004232A (enExample)
NO (1) NO323076B1 (enExample)
NZ (2) NZ530161A (enExample)
SE (1) SE9903997D0 (enExample)
WO (1) WO2001032619A1 (enExample)
ZA (1) ZA200203171B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903998D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
EP2305664A1 (en) 2002-08-30 2011-04-06 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegeneratives diseases
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
CN101247853B (zh) 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
ZA200809659B (en) * 2006-04-13 2010-03-31 Neuraxon Inc 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
WO2009064505A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
EP2220074A4 (en) * 2007-11-16 2012-01-04 Neuraxon Inc 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
KR20100124272A (ko) * 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
AU2009237650B2 (en) * 2008-04-17 2012-05-31 Proximagen Limited Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7
KR20120089190A (ko) * 2009-04-16 2012-08-09 프록시머겐 리미티드 알파 7 니코틴 아세틸콜린 수용체(ｎＡＣｈＲ)의 인돌 유도체 조절체
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
AR086791A1 (es) 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
WO2020045982A1 (ko) * 2018-08-29 2020-03-05 숙명여자대학교산학협력단 치환된 인돌 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 PPARα, PPARγ 및 PPARδ 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787551A (en) * 1954-02-24 1957-04-02 Eastman Kodak Co Compositions stabilized with hydroxyindole
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
KR930702334A (ko) * 1990-09-13 1993-09-08 데이비드 로버트 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아
US5639752A (en) * 1991-11-25 1997-06-17 Pfizer Inc Indole derivatives
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
FR2722686B1 (fr) * 1994-07-22 1996-08-30 Oreal Set, procede, dispositif et composition de teinture des fibres keratiniques
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
CA2387745A1 (en) 2001-05-10
WO2001032619A1 (en) 2001-05-10
CO5251458A1 (es) 2003-02-28
AU1426401A (en) 2001-05-14
KR20020063176A (ko) 2002-08-01
NO323076B1 (no) 2006-12-27
NO20022009D0 (no) 2002-04-26
US6750242B1 (en) 2004-06-15
SE9903997D0 (sv) 1999-11-03
NZ518450A (en) 2004-04-30
MXPA02004232A (es) 2002-10-17
JP2003513071A (ja) 2003-04-08
IL149098A0 (en) 2002-11-10
AU783507B2 (en) 2005-11-03
EP1230216A1 (en) 2002-08-14
NZ530161A (en) 2005-08-26
BR0015195A (pt) 2002-06-18
NO20022009L (no) 2002-07-02
CN1239482C (zh) 2006-02-01
CN1387512A (zh) 2002-12-25

Similar Documents

Publication Publication Date Title
ZA200203181B (en) Positive modulators of nicotinic receptor agonists.
ZA200203171B (en) Positive modulators of nicotinic receptor agonists.
ZA200108846B (en) Glucocorticoid receptor modulators.
AU5203999A (en) Beta3-adrenergic receptor agonists
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
ZA200200298B (en) C-Pyrazole A2A receptor agonists.
ZA200203450B (en) beta2-adrenergic receptor agonists.
ZA991301B (en) Glutamate receptor modulators.
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
IL147198A0 (en) N-pyrazole a2a receptor agonists
MXPA01007033A (es) Heterociclos funcionalizados como moduladores de receptores de quimiocinas.
AU5095000A (en) Receptor interacting protein rip3
GB9903767D0 (en) Receptor assay
AU2441801A (en) Urotensin-ii receptor antagonists
IL146151A0 (en) Human-g-protein receptor
AU2001226387A1 (en) Methods of identifying modulators of the fgf receptor
IL148266A0 (en) Apo-2 receptor antibodies
AU5861900A (en) Receptor agonists and antagonists
AU1745501A (en) Positive modulators of nicotinic receptor agonists
PL348504A1 (en) Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
AU2574801A (en) Selective iGLUR5 receptor antagonists
MXPA01011286A (es) Derivados de ciclocarbamato como moduladores de receptor de progesterona.
AU5572500A (en) Vegf receptor antagonists
ZA200107630B (en) Cyclocarbamate derivatives as progesterone receptor modulators.
ZA200107633B (en) Cyclothiocarbamate derivatives as progesterone receptor modulators.